


# Vascular Lasers and IPLS

| | |
|---|---|
| Journal: | *Journal of Cosmetic and Laser Therapy* |
| Manuscript ID: | draft |
| Manuscript Categories: | Reviews of Treatment Studies |
| Date Submitted by the Author: | n/a |
| Complete List of Authors: | Adamic, Metka; DCP d.o.o. |
| Keyword: | Lasers and light sources, Vascular Malformations, Vascular Laser, Guidelines |
| | |

# VASCULAR LASERS AND IPLS

## Guidelines for care of the European Society for Laser Dermatology (ESLD)

METKA ADAMIČ[1], AGNETA TROILIUS[2], MAURICE ADATTO[3], MICHAEL DROSNER[4] RAJA DAHMANE[5]

[1] Dermatology Centre Parmova, Ljubljana, Slovenia

[2] Laser Section, Dept. of Dermatology University Hospital, Malmö, Sweden

[3] Skinpulse Dermatology Centre, Geneva, Switzerland

[4] Cutaris Zentrum für Haut, Venen und Lasermedizin and Dept. Of Dermatology Technical University, Munich, Germany

[5] Institute of anatomy, Medical Faculty, University of Ljubljana, Slovenia,



## Abstract

Dermatology and dermatologic surgery have rapidly evolved during the last two decades thanks to the numerous technological and scientific acquisitions focused on improved precision in diagnosis and treatment of skin alterations. Given the proliferation of new devices for the treatment of vascular lesions we have considerably changed our treatment approach.

Lasers and noncoherent IPLS are based on the principle of selective photothermolysis and can be used for the treatment of many vascular skin lesions. A

variety of lasers and IPLS has recently been developed for the treatment of congenital and acquired vascular lesions which incorporate these concepts into their design. By properly selecting the wavelength which is maximally absorbed by the target and a corresponding pulse duration, the vascular target can be preferentially injured without transferring significant amounts of energy to surrounding tissues.

Although laser and light sources are very popular due to their non-invading nature, caution should be considered by practitioners and patients to avoid permanent side effects.

These guidelines focus on patient selection and treatment protocol in order to provide safe and effective treatment.

Physicians should always make the indication for the treatment and are responsible to set the machine for each individual patient and each individual treatment.

## Key words

Vascular laser, guidelines, congenital vascular malformations, acquired vascular alterations, intense pulsed light source.

This report reflects the latest data available at the time the report was written (May 2006). Nevertheless, caution should be taken when interpreting the data. Results of future studies may require changes in the conclusion or recommendations set forth in this report. Ideal treatment parameters should be chosen individually, depending on the indication, patient selection, and the system used.

## INTRODUCTION

## Actual knowledge on vascular lasers

Continuous - wave lasers (e.g. argon laser, copper vapour laser) were the first lasers used to treat cutaneous vascular lesions. Their use was often complicated by unacceptable side effects such as scarring and permanent pigmentary alterations. The development of pulsed dye laser (PDL) in the 1980s improved the treatment efficiency and decreased the incidence of these untoward effects. Since then new systems have been introduced, such as KTP-lasers (532 nm), followed by longer wavelength lasers as alexandrite lasers (755 nm), diode lasers (800 – 900 nm) and finally the long pulsed (LP) Nd:YAG lasers (1064 nm), offering a wide range of lasers available for the treatment of different congenital and acquired vascular conditions.

Lasers and intense pulse light sources (IPLS) effects are based on the principle of selective photothermolysis. Upon the laser impact on the vascular target histologically selective vascular injury with coagulation, vessel wall necrosis and perivascular collagen damage with relatively little associated thermal effects on the epidermis and the surrounding dermis can be observed.

As described by Parrish and Anderson, the theory of selective photothermolysis states that a specific chromophore (haemoglobin in case of vascular lesions) can be selectively targeted and damaged with minimal damage to surrounding tissues.

Oxyhemoglobin contained in red blood cells within blood vessels has a maximum peak of absorbtion around 540 nm (alpha peak) and 580 nm (beta peak). This holds true of small superficial vessels mainly located on the face and the neck.

Vessels on the legs are usually located deeper and contain more desoxyhemoglobin. This situation moves the absorbtion curve to the right, from 800 nm to 1200 nm. The longer the wavelength the deeper its penetration into the skin. For example, Nd:YAG lasers (1064 nm) can penetrate millimetres below the epidermis. Very high energy

levels are required to coagulate vessels located so deep. Infrared wavelengths tend to be more effective in treating deeper blue vessels while shorter wavelengths are more effective for superficial red telangiectasias.

Since large structures require more time for sufficient heat absorbtion, longer laser-pulse durations have to be used. Pulse duration has been clearly demonstrated as a milliseconds domain for intradermal vessel treatment. As we must deliver very high energy pulses to thermocoagulate vessels located deeply in the skin, the epidermis should be protected by cooling to minimize damage to melanocytes as well as keratinocytes.

Cooling has become an integral part of laser treatments. Spatially selective cooling can be achieved by active cooling using a cryogen spray, cold sapphire contact handpieces or air pre-cooled and blown onto across the skin surface. These devices promote rapid epidermal cooling to lower temperatures without affecting the target.

When using the contact cooling method the pressure and the low temperatures can blanch the underlying blood vessels minimizing the desired absorption of laser energy by haemoglobin. This can result in lesion persistence in some cases.

## CLINICAL APPLICATIONS

Appropriate treatment begins with a correct diagnosis. A significant number of patients with vascular birthmark receive ineffective and potentially harmful treatment based on misdiagnosis.

A variety of vascular lasers are available for the treatment of different vascular conditions.

A detailed medical history and examination should identify the nature of the vascular condition.

## Classification

In 1996, the **ISSVA (**= International Society of the Study of Vascular Anomalies) classification of vascular anomalies was accepted by the members in Rome. This biological classification is based on clinical and vascular features, natural behaviour, hemodynamic characteristics and biological differences. A multidisciplinary vascular lesion team is highly recommended when determining appropriate therapeutic strategies.

I. **Vascular tumors** ( arise by endothelial hyperplasia):
   - Hemangioma
     - Proliferating
     - Involuting

II. **Vascular Malformations** (arise by dysmorphogenesis and exhibit normal endothelial turnover).
   a. High Flow
      i. Arteriovenous fistula (AVF)
      ii. Arteriovenous malformation (AVM)

   b. Low flow
      i. Capillary Malformation (CM)
      ii. Venous Malformation (VM)
      iii. Lymphatic Malformation (LM)
         1. Macrocystic
         2. Microcystic

iv. Combined

Lasers and IPLS are the treatment of choice for the following vascular conditions:

**Congential vascular lesions**

- Hemangioma
- Port-wine stains (Naevus flammens)

**Acquired vascular alterations**

- Angiofibroma
- Blue Rubber Bleb Nevus syndrome
- Campbell de Morgan angiomas
- Cutaneous lesions of Kaposi sarcoma
- Facial telangiectasia
- Granuloma teleangiectaticum (pyogenic granuloma)
- Leg veins and telangiectasias
- Morbus Ossler (hereditary hemorrhagic telangiectasia)
- Naevus araneus (spider angioma)
- Poikiloderma of Civatte
- Rosacea
- Senile angioma (ruby dot)
- Telangiectasias associated with other conditions:
    - Goltz's syndrom
- Venous angiomas
- Venous lake

**Other skin diseases with vascular alternations**

- Acne
- Early immature striae atrophicae distensae
- Inflammatory linear verrucous epidermal nevus
- Psoriasis
- Red or hypertrophic scars
- Viral warts
- Xanthelasma palpebrarum

***Remember:*** ***NEVER TREAT ARTERIAL MALFORMATIONS WITH LASER OR IPLS!***

## PATIENT SELECTION

Proper patient selection is mandatory for reasonable success rates. Patients present for treatment with vascular lasers have different conditions to treat: from the smallest telangiactasia to the most disfiguring nodular port-wine stain (PWS). It is up to the practitioner to determine whether each individual patient is suitable for laser treatment and if correct technology and skills are available for treatment.

The major goals should target at:

1. Prevention of life or function threatening complications
2. Prevention of disfigurement
3. Minimizing psychological distress
4. Avoiding aggressive procedures
5. Preventing or treating ulcerated lesions

Patients should always be scanned for unrealistic expectations.

## PREOPERATIVE PATIENT EVALUATION

Several factors require consideration before discussing the patient's treatment options.

The following issues should be addressed:

- Does the patient have a lesion amenable to vascular - specific laser treatment?
- Has the patient received previous treatment to the lesion which can attenuate laser treatment?
    - *Vascular lesions that have been treated with electrodesiccation or earlier vascular technology may have developed mild to severe surrounding tissue fibrosis within the treatment area. Similar can happen after the treatment of hemangiomas with irradiation or intralesional application of corticosteroids or sclerosants.*
    - *Side effects of previous laser or IPLS treatments like edema and erythema or any residuals of necrosis should have cleared before the next laser or IPLS session is undertaken in order to prevent additional absorption or treatment of the wrong vessels (erythema).*
- Has the patient suffered from any complications or side effects as a result of the lesion?
- What is the patient's skin type?
    - *Vascular lesions in patients with darker skin types can be treated, but more care has to be taken in selecting an appropriate energy level and in choosing proper treatment intervals.*
        - *The overlying melanin is a competing chromophore for the yellow laser light; it can shield the underlying vascular lesion and reduce the amount of effective light reaching the lesion.*

        - *Higher risk of postoperative hyperpigmentation or hypopigmentation.*
    - *All treatment-induced pigmentary alterations should be completely resolved before additional laser treatment.*
- Does the patient have realistic expectations?
    - *Patients with telangiectasias should be prepared for one to three laser treatments.*
    - *Patients with PWS or hemangiomas typically require six or more treatments within two years to achieve significant clinical clearing*
        - *Patients with PWS located in certain locations (medial cheeks, upper lip, distal extremities) need even more additional treatments and may have incomplete dearing.*

**Proper patient preparation and realistic expectations are paramount to the success of the treatment.**

## PATIENT INFORMATION AND CONSENT

Most vascular lesions require more than one laser treatment and 4 to 6 or even more weeks between treatments for optimal tissue healing. It is important that patients are fully aware of both initial healing time (in average 7-10 postoperative days) and overall time needed for the complete treatment protocol.

- Before treatment, patients should be questioned about a history of:
    - postinflammatory hyperpigmentation,
    - excessive scarring,

- Patients should be advised to avoid excessive sun exposure before, during, and after laser treatments; sun exposure can contribute to postinflammatory changes or limit the effectiveness of the treatment.

Possible side effects and complications should be discussed in detail and should be added to the consent form to be signed by the patient before the treatment is started.

## PRE-LASER TREATMENT CARE

In order to achieve optimal results the patient should be advised to get the palest skin colour possible. A broad - spectrum sun screen with SPF 50+, started at least 4 weeks prior to the first treatment, would help to get paler skin even during summer time. In severely tanned subjects bleaching agents are recommended, prior to the laser therapy. The skin area to be treated should be make-up free.

Laser treatment is not a painless procedure. Most patients do not require local anesthesia for this procedure. Topical anaesthetic cream could be applied one hour before the scheduled treatment. A disadvantage of topical anesthetics is the vasoconstriction that occurs, which may make it difficult to see all the vessels. However, anaesthesia is not suggested in general in adult patients because pain is the best early warning system to prevent side effects caused by heat destruction.

## PREOPERATIVE CHECKLIST

Using a checklist can be helpful when first evaluating a patient for vascular laser treatment. The data obtained are a part of the patient's medical record and can be referred to or updated during subsequent patient visits.

- Prior to laser treatment detailed pre - treatment education is initiated with information sheets.
- Preoperative photographs should be taken before laser treatment and upon occurence of side effects.

Before laser treatment, the patient must sign an informed consent and be given the opportunity to ask further questions.

## TREATMENT

Different lasers systems are used at different fluences, pulse widths and spot sizes to treat the same vascular lesions.

The physician should choose proper treatment parameters for each laser system, vascular lesion and body location.

Treatment protocol must be based individually as to patient's clinical examination, skin type, history and tissue response.

Before the laser or IPLS treatment every person in the treatment room (including the patient) should wear protective goggles designed for the specific wavelength or wavelength range emitted by the light source.

Before the start of and during longer treatment sessions the equipment should be checked.

In laser therapy each of the following 4 parameters has to be selected individually and adapted to the clinical situation:

- wavelength,
- beam diameter (spot size),
- pulse duration,
- fluence (energy density per $cm^2$).

The optimal parameters vary considerably with regard to laser/IPLS, vascular lesions (indication) and the patient. Therefore a test treatment on a representative but small (and hidden) area is recommendable.

**Treatment principles:**

Smaller vessels need shorter pulses, larger vessels need longer pulses.

The deeper the blood vessel is located in the dermis, the larger the spot size, the longer the wavelength and the longer the pulse duration should be, combined with cooling to protect the epidermis

Darker skin types need longer pulses and longer pulse intervals.

To thermocoagulate leg veins, the system should be able to deliver very high energy pulses through large spot sizes to enhance scattering into the dermis. When a larger spot size is used the dermal penetration is deeper. When a spot size is reduced, a higher fluence is required to achieve the same result.

When required, a thin layer of gel (optical indifferent ultrasound gel) is applied to the area to be treated in order to enable the contact hand piece to glide on the skin and to improve the light penetration into the skin as well as the temperature exchange with the skin surface. Alternatively thin gel pads could be used and are helpful during KTP laser treatment cooling the surface, avoiding secondary erythema during treatment and magnifying smaller vessels. The contact hand-piece touches the skin surface over the vascular lesion without pressing. The contact method is mainly used with diode and Nd:YAG lasers as well as with flash lamps. The hand piece of the (flashlamp-pumped) pulsed dye laser PDL (FPDL) and pulsed alexandrite laser normally operates as a non - touch system with a distance tip. Parallel cold air

cooling improves the use of these laser types in order to increase the possible fluence and to reduce the risk of side effects.

Laser light penetration is decreased in more darkly pigmented skin. Higher fluences are required to produce similar clinical effects in darker-skin types but should be administered with care to prevent side effects caused by higher absorption of the pigmented epidermis.

Areas prone to scarring such as the anterior chest or neck as well as areas where skin is fragile (periorbital region) require 10-20% reduction in fluence. Epidermis on the legs tends to be more sensitive to injury. A reduction of fluence is also recommended in case of underlying bones reflecting the laser beam. Care should be taken to prevent pulse overlapping by more than 10% in order to minimize the risk of scarring and textural changes.

The treatment should start on a small but representative test area using the proper pulse duration, spot size and the highest tolerable fluence.

The treatment is painful, but the pain should always be tolerable. If the patient is complaining about intolerable pain the risk of adverse effects is high. Signs of side effects and proper treatment endpoints are very close and should be sorted out carefully as they may be different in each laser or IPLS.

Laser treatment of vascular lesions usually requires more than one treatment session.

Intervals between each sessions should be 4 - 6 weeks or even more, specially in darker skin types.

Compression has not been demonstrated to be necessary for good results following laser treatment of leg telangiectasias.

## TREATMENT OF DIFFERENT VASCULAR LESIONS

**Facial telangiectasias**

are common cause of cosmetic concern. Current treatment modalities present various untoward effects and limits.

Classification:

- simple or linear,
- arborizing, spider or star,
- punctiform,
- papular.

Red linear and arborizing telangiectasias often occur on the face, especially on the nose, midcheeks, and chin. They measure 0.1 to 1.0 mm in diameter and represent a dilated venule, capillary or arteriole. They probably result from a variety of factors (genetic predisposition, presence of other diseases, hormones, physical stress, chronic sun exposure, surgical or physical trauma, hormonal considerations such as corticosteroid use, pregnancy, alcohol or estrogen ingestion...).

Choice of the appropriate system:

First choice: FPDL, KTP (532 nm), IPLS.

Second choice (use with maximal care): APDL, Argon, Copper vapour.

The size and configuration of the telangiectasia will determine the optimal treatment laser.

The pain associated with laser treatment of telangiectasias varies according to the laser used and the size of the area treated. A topical anesthetic cream can be applied before treatment to reduce patient discomfort. However, it causes vasoconstriction and can therefore have negative influence on the outcome.

Cooling system (contact, cryogen spray and cold air cooling) can cause an immediate prelaser anesthesia. Epidermal cooling can reduce the epidermal surface

temperature, thereby reducing treatment discomfort and protecting the epidermis from thermal injury.

**Rosacea**

Patients with rosacea often complain of facial flushing and erythema. Telangiectasias are frequently present and are unresponsive to classic topical or systemic therapy. As vessel dilatation and higher permeation of inflammation-inducing factors are pathogenic in rosacea, the treatment of these vessels also contributes to other phases of rosacea (papular and papulo-pustular rosacea).

Choice of the appropriate system:

FPDL, KTP (532 nm), IPLS.

Second choice (use with maximal care): APDL, argon, copper vapour.

The erythema (first stadium of rosacea) can only be treated with FPDL, KTP or IPLS.

**Hemangiomas**

Cutaneus hemangiomas are the most common tumors arising in infancy. More than 50% of hemangiomas develop in the head and neck regions. Although it may be present at birth, it usually becomes apparent within few weeks of life as small erythematous macular patch, localized telangiectasia or hypopigmented spot in a neonate with growth occurring over the following few months. This rapid phase of growth is referred to as the proliferative phase. The proliferative phase is followed by a gradual spontaneous involution (the involution phase) which is complete in 50 % by 5 years and 70 % by 7 years of age.

An accurate diagnosis and a clear understanding of the differences between vascular malformations (PWS, birthmark) and hemangiomas are important since the natural

history and the treatment recommendations for these two conditions are very different.

The majority of strawberry hemangiomas are of cosmetic concern. Some hemangiomas may cause serious problems, most complications occur during the proliferative phase.

Treatment requirements:

- All hemangiomas in childhood should be treated as early as possible to prevent the proliferative phase (and its complications) as well as the psychosocial implications associated with persisting hemangiomas.
- In the following cases a treatment must be started:
  - hemangiomas that cause functional or structural abnormalities (e.g., airway obstruction, ophthalmologic disturbances,…),
  - hemangiomas that ulcerate and bleed,
  - hemangiomas with secondary infection,
  - hemangiomas that may result in disfigurement or scar,
  - hemangiomas with the slightest appearance of growth must be treated to avoid further cosmetic or functional impairment.

*Remember that large cervicofacial hemangiomas can be associated with posterior fossa brain malformations, including Dandy - Walker malformations*.

It is important not to underestimate the psychosocial implications of this condition for both children and parents.

<u>Choice of the appropriate system:</u>

- FPDL, IPLS, Nd:YAG, KTP

Treatment will not minimize the deeper growth, but will only affect the superficial component of hemangioma. Frequent treatments at 2-3 weeks intervals at higher

energies should be performed. Although treatment should begin early when the hemangioma is just starting to occur, it is often difficult to predict whether or not there will be a superficial and deep component; the deeper component may still develop despite successful treatment of the superficial component.

The management of patients with potentially problemtic hemangiomas should involve a **multidisciplinary approach**. For life threatening proliferative hemangiomas, a combination of laser therapy, intralesional and systemic glucocorticoids, topical imunosupression with imiquimod and other agents may be required.

The complications of bleeding and ulceration respond very well to laser therapy. To stop bleeding or ulceration usually one or two treatments are required and often there is a prompt response.

In the incompletely regressed capillary hemangioma of the older child, superficial ectatic blood vessels can be treated with the vascular laser.

In view of contemporary anesthetic techniques, safer and more selective laser therapy, and conservative tissue-sparring surgical approach, we recommend an early intervention whenever a hemangioma in childhood is diagnosed.

Treatment:

Most haemangiomas treated with FPDL or IPLS do not require general anesthesia because the duration of treatment is limited and discomfort is minimal.

Patients older than 1 year can be treated either with topical anesthetics (EMLA) or with nerve blocks or in general anaesthesia.

Patients treated with the Nd:YAG laser or those with extensive hemangiomas may require general anesthesia.

**Kassabach Merritt Phenomenon**

Some hemangiomas cause life threatening conditions. In such a condition, the hemangioma destroys the blood platelets, which can in turn result in a fatal bleeding disorder. Any large hemangioma should be suspect for Kassabach-Merritt syndrome, and blood platelet levels should be checked if a child has an aggressive, large hemangioma prior to six months of age.

Life threatening! Never use laser treatment! Systemic steroids or Vincristin!

**Vascular malformations, port-wine stains (PWS)**

Vascular malformations in general increase in size throughout life, because of the continual intraluminal hydrostatic pressure. During adolescence some vascular malformations rapidly expand while others do not. They are subcategorized as capillary, venous, arterial, lymphatic or a combination of these. Vascular malformations do not involute.

PWS are present at birth. They are not neoplasms but instead exhibit normal endothelial turnover and are errors of vascular morphogenesis which manifest as various vascular channel abnormalities. They are congenital vascular malformations composed of a superficial collection of ectatic vessels that grow commensurably with the child. They may occur anywhere in the body. The vessels are located in the papillary and superficial reticular dermis, with a mean vessel depth of 0.46 mm. Initially, a PWS may appear as a pale, erythematous macule or patch that darkens in colour with age. The surface may become raised and nodular, especially as the individual ages. There may also be soft - tissue hypertrophy within the affected area, particularly in the lip region. The growth of the lesion is commensurate with the child's growth and it does not resolve spontaneously.

When to start with laser treatment?

Any PWS should be treated as they turn darker and thicker with age.

- There is a marked reduction in PWS in children whose treatments begin at less than 1 year, in order to prevent progression and thus increase the likelihood of complete removal.
- Younger children may have smaller and more superficial vascular malformations that are more amenable to treatment.
- Some authors have reported that children between 3 and 8 years of age required more treatments for clearance of the lesion than either younger or older children - residual ectatic blood vessels in these children grow rapidly between laser treatment in response to intrinsic growth factors.
- The morbidity is associated with the malformation in patients of all ages and in the patient's families.

Choice of the adequate system: FPDL, IPLS, Nd:YAG, KTP (large spot).

**Grade I:** *Earliest, smallest vessels 50 – 80 µm. Light and dark pink macules.*

- FPDL, KTP, IPLS.

**Grade II:** *Clearly indistinguishable, more advanced, 80-120 µm with individual vessels clearly visible to the bare eye.*

- FPDL (long pulse), KTP, IPLS.

**Grade III**: *Reddish patches with vessels even more ectatic 120 – 150 µm.*

- FPDL (long pulse), KTP (large spot), IPLS.

**Grade IV**: *Thick, purple, palpable, possibly nodular. Advanced dilated vessels > 150 µm.*

- IPLS, Alexandrite, Nd:YAG (avoid the orbital area), Diode.

Treatments are repeated at an interval of about 8 weeks.

Some individuals appear to be able to tolerate large treatments without distress. Topical anesthetic agents can assist (EMLA), but it is not indicated for children under 6 months (excessive absorption on highly vascular surfaces and formation of methemogolobin causing cerebral hypoxemia). Infiltrational and nerve block anesthesia can be used. Majority of children will require general anesthesia.

**Efficiency of laser treatment depends on:**

- The patient age
  - *Since the PWS become thicker and darker as the child ages, it is best to start treatment as early as possible. The earlier the treatment is started, the easier and better they clear.*
- Lesion colour
  - *Pink PWS, especially in children, are more difficult to lighten than mature red PWS.*
  - *Deep purple and nodular port-wine stains respond least well to laser treatment, longer wavelengths (755 nm, 800-900 nm and 1064 nm) are more suitable.*
- Depth and size of the vascular components
    - *Malformations may have a deep vascular component that can not be reached with a FPDL, but by Nd:YAG laser or IPLS.*

- *Smaller PWS (less than 20 $cm^2$) clear better than larger ones, irrespective of age.*

- Location of the port-wine stain:
  - *Central forehead lesions give the best response and are in order of effectiveness followed by periorbital lesions, peripheral facial and neck lesions.*
  - *Centrofacial lesions and those in the* V2 *distribution are less responsive to laser therapy than are PWS located elsewhere on the face.*
  - *PWS on the distal extremities are more difficult to clear than lesions on the proximal extremities.*
  - *PWS on the head and neck respond more favorably to treatment than lesions elsewhere on the body.*
- There is decreasing effectiveness in the response of PWS to successive laser treatments, but there is still slow improvement with continued treatment.

**Sturge Weber´s syndrome (SWS)**

The location of PWS may suggest that the child is at risk for underlying syndrome. 10-15% patients with PWS occurring in the ophthalmic (forehead and upper eyelid) region may be at risk for developing SWS, a sporadic neurologic disorder associated with ocular and leptomeningeal abnormalities. All children presenting with a PWS in this distribution should be given ocular and neurological evaluation.

Laser treatment: Careful! Faster scarring due to greater absorption!

**Klippel Trennaunay syndrome (KTS)**

Patients with PWS occurring on the limbs should be evaluated for underlying KTS, which presents as a progressive overgrowth of the affected extremity.

**Blue Rubber Bleb Nevus syndrome**

Blue Rubber Bleb Nevus Syndrome (BRBNS) is a rare disorder characterized by multiple cutaneous venous malformations in the skin and gastrointestinal tract associated with intestinal hemorrhage and iron deficiency anemia. Other organs may also be involved. BRBNS has a potential for serious or fatal bleeding. The causes of this syndrome are unknown. Around 200 case reports were published by the year 2003. It is important to **treat early** when the lesions are small, because when they grow bigger they need to be excised, which could prove to be quite difficult due to the locations and the multitude.

Choice of adequate system:

- Nd:YAG, IPLS, $CO_2$, diode

No general anaesthesia is required (EMLA cream, contact cooling and double dose paracetamol).

**Morbus Osler - hereditary haemorrhagic telangiectasia**

Choice of adequate system:

- Nd:YAG, diode

Treat frequent: every 3 - 4 weeks in the beginning. Diode laser treatment may leave a small depression as large as the telangiectatic papule after the treatment!

**Spider angioma**

They occur in up to 15% of completely normal persons, more frequently in children. They occur in large numbers during pregnancy. They are also characteristicaly found in liver disease, of which they may be a presenting sign. The main vessel of the spider is an arteriole.The blood flows from this to the periphery, and then passes into a cappillary network.

Choice of adequate system:

- KTP, FPDL, IPLS, Nd:YAG

Second choice: Argon, copper vapour.

**Poikiloderma of Civatte (Erythosis interfollicularis colli)**

Poikildoderma of Civatte is a variant of telangiectasia associated with more or less symmetrical atrophy and pigmentary irregularity of the upper chest, lateral neck, and occasionally the lateral cheeks, but spares the area shaded by the chin. Induced by sun exposure, poikiloderma is unresponsive to most standard forms of therapy.

Choice of adequate system:

- FPDL, IPLS

Second choice: KTP (Caution! It can cause scarring if inadequate parameters are used)

It is important to reduce the fluence when treating scar-prone areas such as the neck and upper chest and to use larger spot sizes, such as 10 mm. Careful with the overlying hyperpigmentation, which might be present at the same time (Erythromelanosis intefollicularis colli)!

**Granuloma teleangiectaticum (pyogenic granuloma)**

These granulomas are benign vascular tumors that often ulcerate and bleed with trauma and are most commonly seen in children. They may occur after insect bites or minor traumata.

Choice of adequate system:

- Nd:YAG, IPLS

Multiple treatments.

Second choice:

- $CO_2$, argon, FPDL

Low fluences should be used because of the high incidence of posttreatment hypopigmentation and possible scarring.

**Venous lakes**

A form of senile angioma occurring on the face, lips and ears of elderly patients. Histologically, they consist of greatly dilated, thin-walled venules without the proliferation of vascular tissue of the true angioma. There is degeneration of the supporting convective tissue.

Choice of adequate system:

- KTP, Nd:YAG, FPDL, IPLS

**Cherry angioma**

Cherry angiomas are produced by spherical and tubular dilatations of capillary loops in dermal pappilae with tortuous cross-connections between individual loops.

These are particulary common on the trunk of middleaged or elderly people.They disappear in extreme old age.

Choice of adequate system:

- KTP, Nd:YAG, IPLS, FPDL

## Leg veins and telangiectasias

In the past, the use of lasers and light sources in treating lower extremity blood vessels has not been as successful as laser treatment of facial teleangiectasia. Among several reasons for this partial success in the past are increased hydrostatic pressure on the lower extremities, anatomy of lower extremity blood vessels and occasionally association with underlying venous disease.

The variation in size, blood flow, depth and type of vessel make this procedure more difficult to manage with a laser. In comparison to facial teleangiectasia, leg veins have thick surrounding adventitial tissue and increased basal lamina.

There exist clinical observations and theoretical considerations which favour longer wavelengths and longer pulses for the treatment of leg veins.

The longer the wavelengths, e.g. 1064 nm Nd-YAG laser, the better the advantage of deeper penetration, the better the absorption in deoxyhemoglobin and the greater the sparing of the epidermis. An additional benefit of longer wavelength laser is a decreased melanin coefficient absorption.

By selectively cooling the epidermis during the laser treatment while maintaining peak temperatures of the dermal blood vessels, the practitioner minimizes the risk of damage to the skin.

To thermocoagulate leg veins of deeper location and of greater diameter, the laser systems should be able to deliver very high energy pulses through large spot sizes to enhance scattering into dermis. Pulse duration has been clearly demonstrated to be in the milisecond domain for intradermal vessel treatment. The longer pulse duration is closer to the thermal relaxation time of larger vessels (1-50 msec), thus being able to target larger-diameter vessels (0,1-2mm) including leg telangiectasia.

Indications:

Lasers sholud be considered prior to sclerotherapy in patients:

- with needle phobia,
- who do not tolerate sclerotherapy,
- who fail to respond to sclerotherapy,
- who have developed untoward side effects from sclerotherapy,
- are prone to teleangiectatic matting.

Others:

- fair-skinned persons who either have vessels of diameter less than 2 mm or require treatment of foot and ankle vessels difficult to treat with sclerotherapy,
- patients who are unwilling or unable to tolerate compression hosery or bandaging required after sclerotherapy.

Lasers and IPLS enable treatment of the following:

- Spider veins: 0,2-2 mm red and blue vascular ectasias, often associated with larger reticular veins.
- Reticular veins: “non bulging” subcutaneous veins ranging up to 5mm in diameter.
- Telangiactasias: 0,2–1 mm, reside about 300 μm below the skin surface, from dark blue to bright red.
    - Bright red: smaller (0,2-0,5 mm),
    - blue: deeper vessels, regardless of size and degree of oxygenation.

Choice of adequate system:

Over the last years Nd:YAG Laser systems became the lasers of choice for leg vein treatment. Additionlly isolated, relatively small diameter (less than 1 mm) leg teleangiactasias:

- KTP, FPDL (long pulse), Nd:YAG, IPLS

Larger-diameter, moderately deep leg vessels:

- Nd:YAG, alexandrite, diode, IPLS

Sometimes simultaneus treatment with lasers of longer wavelengths and pulse durations for larger veins, in combination with lasers of shorter wavelengths and pulse durations for the smaller veins, may provide comparable outcomes to treating patches of heterogenous vessels by sclerotherapy.

## Treatment endpoints and initial signs of adverse effects

By different vascular lasers we are able to induce selective vessel damage and perivascular changes with relative sparing of the epidermis and surrounding dermal tissue.

The ideal immediate response to treatment with vascular laser is coagulation of the intradermal vessel with no other apparent effect.

This effect can be observed in form of bluish or grayish discoloration visible on skin surface.

In leg veins blanching or disappearing of the vessel may also occur.

## SIDE EFFECTS

Complications from laser treatment are reduced by operator education and experience.

- Pain
  - The snapping and burning sensation of each laser pulse can produce a minimal to moderate amount of discomfort.
    - *An anesthetic cream or injection can be used to block the pain. However, pain is an important marker of possible side effects occuring.*
- Purpura, bruising
  - Immediately after the laser treatment the area will in some cases appear gray or blue - black in colour.
    - *The discoloration will fade over the next 7-10 days*.
- Bleeding, hematoma, disruption
    - Can be caused by inadequate treatment parameters (e.g. too short pulse duration combined with too high fluences).
- Swelling
  - Within few minutes after the laser treatment an erythema and oedema will occur over the treatment area. Areas most likely to swell are under the eyes and neck.
    - *The swelling subsides within 3-5 days if ice is regluarly applied.*
  - Parallel and post cooling will deminish the amount of oedema.
- Discoloration, blisters or scabs
  - Develops rarely (mostly caused by overtreatment).
  - Grey or pale white discoloration of the epidermis is a sign of early dermal damage indicating inappropriately high fluences. This sign will only last a few seconds.

- Blister formation, epidermal disruption and epidermis necrosis (and dermis necrosis in severe cases) will follow.
  - *Intense cooling, reduction of fluence and prolongation of the pulse duration are consequent reactions.*
  - *Can take 1 to 2 weeks to resolve.*
- These findings can be immediate or delayed, it is important to carefully observe the treated test spot for at least five minutes before proceeding with full treatment.

- Infection
  - Increasing (instead of decreasing) swelling, redness, crusting, pain, and fever can be an indication for an infection.
    - *Topical antiseptics or oral antibiotics should be used.*
- Reactivation of Herpes simplex on the face (when the face is treated) or genital (when legs are treated)
  - *Preventive oral virostatic therapy (acyclovir, valcyclovir, famcyclovir) is recommended when the patient has frequent herpetic recidives (more than 6 per year), starting the day before laser treatment.*
- Skin darkening (hyperpigmentation)
    - *Eventually fades within 2 to 6 months.*
  - This reaction is more common in patients with darker skin type (Fitzpatrick III-V). The darkening worsens if the laser-treated area is exposed to the sun.
    - *Topical bleaching cream, such as hydroquinone, can be used either as pre-treatment (2 weeks prior to laser or IPLS) or to speed up the blanching.*
- Skin lightening (hypopigmentation)

- Mostly caused by overtreatment.
  - *Pale areas usually darken or repigment within 3 to 6 months.*
  - *Could be persistent, most frequently on the neck, legs and chest.*
- Skin texture changes
  - Mostly caused by overtreatment.
  - In case of excessive fluences or overlapping laser spots are used.
- Scarring
  - Mostly caused by overtreatment.
  - In case of excessive fluences, multiple pulses or overlapping laser spots are used.
  - Can occur on disruption of the skin surface.
  - Following all advised postoperative instructions can reduce this possibility.
- Lesion persistence, non responders
  - Some vascular lesions may not go away completely despite the best effort made by the doctor. This may also be the case in lesions with high blood flow.

The likelihood of these adverse events in any individual depends on vessel diameter, vessel colour, location, intraoperative technique, pre- and postoperative care.

## POST-LASER TREATMENT CARE

After alexandrite, diode, Nd:YAG lasers or IPLS the skin appears minimum erythematous with oedema. After PDL the skin may appear purpuric with surrounding tissue hyperemia.

- To prevent or reduce swelling, post-cooling with ice packs (or cold air) is adviced on larger areas such as cheeks or neck after the laser treatment until any pain or redness has disappeared. The ice or frozen cold pack should be wrapped in a soft cloth and applied for 10-15 minutes each hour for 4 hours or as long as burning sensation is noticed.
- If the treatment has been performed close to or around the eye there will be a risk of periocular edema. The edema under the eyes may develop 1-2 days after laser therapy of the cheeks. Patients should be instructed to sleep with an extra pillow to encourage gravitational removal of leaked oedema fluid.
- Patients should be instructed to avoid sun exposure (unless sun protection is used, SPF 50+) to prevent post-inflammatory hyperpigmentation.
- The importance of not picking or scratching at treated areas.
- A topical antiseptic ointment could be applied to the irradiated areas to avoid secondary infection during the healing period (7-10 days).
- A mild, non-irritating soap can be used twice daily on the treated areas.
- Makeup can be used immediately after treatment except if blistering occurs
- Showers are allowed, but prolonged bathing or sauna is not advised.
- The treated area is extremely delicate and must be handled with care during the initial healing phase (7-10 days).
- Patient should avoid swimming and contact sports while skin is healing.
- In case of blistering with open wounds hydrocolloid dressings should be applied to avoid crust formation. The operator may consider use of topical antibiotics.

It may take a few weeks after the bruising or scabs to disappear to notice fading of the primary vascular lesions. During the next weeks the absorption of coagulated

treated vessels will occur by the surrounding tissue. The response to the treatment should not be evaluated for several weeks until the healing process is complete. Leg vein results may not be visible until 2-3 months after treatment.

## PHYSICIAN QUALIFICATIONS

Laser technology has become so advanced that specific cutaneous targets can be eliminated without adverse sequelae to the normal overlying and surrounding skin. Despite the specificity of lasers used today, complications may still appear. Although some of complications are laser-related, many are still caused by an operator error, either in consciousness or postoperative mismanagement.

When proper laser parameters and postoperative care are applied in adequately chosen patients, the risk of complications remains low.

Treatments performed by a physician, maximal use of time and resources, help to achieve a high safety standard.

The physician treating vascular lesions with lasers or IPLS should have a completed residency training in an appropriate specialty area such as dermatology and he/she should have general knowledge of basic laser physics, laser-tissue interaction, and laser safety. Before starting treatments, the physician should attend corresponding laser training courses including hands-on experience or work under supervision of an appropriately trained laser expert. The physician has to be trained at least one year and should be given enough insight into adverse effects, and how to avoid them.

Standardized informed consent documentation should be made available for every single medical/surgical act.

Continuous medical education (CME) as well as active membership in a medical society specialized in laser applications in medicine (e.g. ESLD, ASLMS, national laser societies, etc) are recommended.

## SAFETY PRECAUTIONS AND ADVERSE EFFECTS

Since all vascular lasers and IPLs are designed for deep penetration and strong absorption in haemoglobin, they have a high potential for eye injury (thermal destruction of retina and iris). Treatment in the area near the eye is not recommended unless the eyes are covered with metal lenses, and adequate eye protection googles are obligatory for all persons within the operating room (including the patient).

Methods to reduce the incidence of adverse effects include lightening of the skin and sun avoidance prior to laser treatment, cooling of the skin during treatment, sun avoidance and protection after treatment. Cooling devices, either spray, cold air or contact cooling, are helpful in protecting the epidermis but may not be sufficient to protect tanned or darker skinned patients. Patients with a tan should delay treatment until the tan fades.

Individuals with a history of hypertrophic scarring or keloids should be treated with caution (test spot!).

### Pregnancy

Although vascular laser or IPLS physically have no impact on pregnancy, most laser manufacturers exclude the use of these lasers in pregnant women in their application notes. The treatment does cause pain and can be distressing.

Laser treatment should be discontinued in the first two trimesters of pregnancy. In the third trimester laser treatment of vascular lesions can be undertaken within the responsibility of the physician, as the foetus is completely formed and no risk of foetal malformation is known. But, in most situations, laser may be postponed until after delivery.

## Disclaimer

Adherence to these guidelines will not ensure successful and safe treatment in each and every situation. The ultimate judgement regarding the suitability of any specific procedure must be made by the physician in light of all the circumstances presented by the individual patient.

## Supporting evidence

These guidelines of care for vascular lasers are based on the experience of the members of the European Society for Laser Dermatology (ESLD) and an review of literature articles. The articles supporting the statements mentioned in these guidelines are listed in the bibliography (Appendix 2).

## Appendix 1: Abbrevations

| | |
|---|---|
| $cm^2$ | centimeter square |
| J | Joule |
| mm | millimeter |
| ms | milliseconds |
| nm | nanometer |

| | |
|---|---|
| Nd:YAG | Neodymium:Yttrium Aluminium Garnet |
| FPDL | pulsed dye laser (flash lamp pumped) |
| APDL | pulsed dye laser (argon laser pumped) |
| KTP | |
| IPLS | intense pulsed light source |
| PWS | port-wine stains |
| SPF | sun protection factor |
| UV | ultra violet |

## Appendix 2: Bibliography


1. *Anderson RR, Parish JA. The optics of human skin. J Invest Dermatol 1981; 77:13-19.*
2. *Anderson RR, Parish JA.Selective photothermolysis: precise microsurgery by selective absorbtion of pulsed radiation. Science 1983; 22:524-527.*
3. *Anderson RR. Laser - tissue interactions. In: Goldman MP, Fitzpatrick RE, eds. Cutaneous laser surgery. St. Louis: Mosby, 1994; 1-17.*
4. *Herd, RM, Dover JS, Arndt KA. Basic laser principles. Dermatol Clin 1997; 15:355-372.*
5. *Rosio TJ. Basic Laser physics. In: Roenigk RK, Roenigk HH. Roenigk and Roenigk's Dermatologic Surgery. Principles and Practice . 2nd ed. New York: Marcel Dekker Inc, 1996:947-975.*
6. *Sheehan-Dare RA. The use of lasers in dermatology. Hosp Med. 2001;62(1): 14-17.*
7. *Rosio TJ. Basic laser safety. In: Roenigk & Roenigk's dermatologic surgery: Principles and practice. 2.nd ed. New York Marcel Dekker,1996:977-975.*

8. Goldman MP, Fitzpatrick RE. Cutaneous laser surgery: the art and science of selective photothermolysis. St. Louis: Mosby-Year Book; 1994.
9. Lanigan SW. Laser treatment of vascular lesions. In: Goldberg DJ, Laser dermatology. Springer-Verlag Berlin Heidelberg,2005:13-35.
10. Alster TS, Lupton JR. Lasers in dermatology. Am J Clin Dermatol 2001;2(5):291-303.
11. Massey RA, Marrero G, Goel-Bansal M,Gmyrek R, Katz BE. Lasers in dermatology: a review. Cutis 2001;67(6):477-484.
12. Anderson RR. Lasers in dermatology–a critical update. J Dermatol 2000; 27(11):700-705.
13. Mazer JM. Indications for medical lasers in dermatology. Presse Med 2002;31(5):223-231.
14. Chapas AM, Geronemus R. Our approach to pediatric dermatologic laser surgery. Lasers Surg Med 2005; 37:255-263.
15. Alora MB, Arndt KA. Lasers for vascular lesions. Cosmetic Dermatology 1998:33-40.
16. Alster TS. Laser treatment of vascular lesions. Skin & aging 1998;8:27-28.
17. Alster T. Laser treatment of vascular lesions. In: Cutaneous laser techniques. 2nd ed. Philadelphia: Lippincott Williams& Wilkins,1999:33-51.
18. Diericx CC, Casparian JM,Venugopalan V et al.Thermal relaxation of port wine stain vessels probed in vivo: the need for 1-10 milisecond laser pulse treatment. J Invest Dermatol 1995, 105:709.
19. Cantatore JL, Kriegel DA. Laser surgery: An approach to the pediatric patient. J Am Acad Dermatol 2004;50:165-184.

20. Rothfleisch JE, Kosann MK, Levine VJ, Ashinoff R. Laser treatment of congenital and aquired vascular lesions. A review. In: Update on lasers. Dermatologic clinics 2002; 20(1):1-36.

21. Williams EF, Stanislav P, Dupree M, Mourtzikos K, Mihm M, Shannon L. Hemangiomas in infants and children. An algorithm for intervention. Arch Facial Plast Surg 2000;2:103-111.

22. Raulin C, Schroeter CA, Weiss RA, Keiner M, Werner S. Treatment of Port-wine Stains with a Noncoherent Pulsed Light Source. Arch Dermatol. 1999;135:679-683.

23. Sadick NS, Prieto VG, Shea CR, Nicholson J, McCaffrey T. Clinical and Pathophysiologic Correlates of 1064-nm Nd:YAG Laser Treatment of Reticular Veins and Venulectasias. Arch Dermatol. 2001;137:613-617.

24. Laube S, Lanigan SW. Laser treatment of rosacea. J Cosmetic Dermatology 2002; 1:188-195.

25. Metry DW, Herbert AA. Benign Cutaneous Vascular Tumors of Infancy. Arch Dermatol. 2000;136:905-914.

26. Poetke M, Philipp C, Berlien HP. Flashlamp-Pumped Pulsed Dye Laser for Hemangiomas in Infancy. Arch Dermatol. 2000;136:628-632.

27. Raulin C, Hellwig S, Schönermark M. Treatment of a non-responding port-wine stain with a new pulsed light source. Laser Surg Med. 1997; 21:203-208.

28. West TB, Kovak SJ. Laser treatment of facial and leg telangiectasias. In: Alster TS, Apfelberg DB, eds. Cosmetic laser surgery, 2nd ed. New York: Wiley-Liss, inc.,1999:255-277.

29. Goldman MP, Weiss RA. Treatment of poikiloderma of Civatte on the neck with an intense pulsed light source. Plast Reconstr Surg 2001;107.1376-1381.

30. Duffy DM. Lasers for treatment of leg veins: a comparison with sclerotherapy. Skin & Aging 1999;58-67.

31. Goldman MP, Fitzpatrick RE. Pulsed- dye laser treatment of leg telangiectasia:with and withuot simultaneous sclerotherapy. J Dermatol Surg Onc 1990;16:338-344.

32. Katz B: Laser therapy and sclerotherapy in the treatment of large and small spider veins. Cosmetic dermatology 1998:34-41.

33. Narukar V Laser therapy of lower extremity telangiectasias. Cosmetic Dermatology 1998:11-15.

34. Kauvar ANB. Role of lasers in the treatment of leg veins. In: Arndt KA, Dover JS, Controversies and conversations in cutaneus laser surgery. AMA press, 2002:165-169.

35. Hsia J, Lowey JA; Zelickson B. Treatment of leg telangiectasia using long-pulse dye laser at 595 nm. Laser Surg Med, 1999;20:1-5.

36. Mc Daniel DH, Ash K, Lord J Newman J, Adrian RM, Zukowski M. Laser therapy of spider leg veins; clinical evaluation of a new long pulses alexandrite laser. Dermatol Surg, 1999; 25:52-58.

37. Kauvar ANB. Optimizing treatment of small (0,1-1,0 mm) and large (1,0-2,0 mm) leg telangiectasia with long pulsed Nd-YAG laser (abstract). Laser Surg med, 2001(suppl 13): 24.

38. Weiss RA. Treatment of leg veins with lasers and intense pulsed light. In: Arndt KA, Dover JS, Controversies and conversations in cutaneus laser surgery. AMA press, 2002:175-179.

39. Weiss RA, Dover JS. Lasers surgery of leg veins. Update on lasers. In: Dermatologic clinics. Philadelphia: W.B. Saunders Company, 2002;20 (1):19-36.

40. Goldman MP. Phototermal treatment of leg teleangiectasia. Contraversies and conversations in cutaneus laser surgery. AMA press, 2002:171-174.

41. Adrian RM, Clinical and histologic findings of leg veins treated with laser. In: Arndt KA, Dover JS, Contraversies and conversations in cutaneus laser surgery. AMA press, 2002:181-189.

42. Kahan RS. Comparative pilot study evaluating the treatment of leg veins with a long pulse Nd:YAG laser and sclerotherapy. Lasers Surg Med 2003;32(4):251.

43. Omura NE, Dover JS, Arndt KA, Kauvar AN. Treatment of reticular leg veins with a 1064 nm long-pulsed Nd:YAG laser. J Am Acad Dermatol 2003;48(1):76-81.

44. Kauvar ANB. Laser treatment of leg veins. In: Fitzpatrick RE, Goldman MP; Cosmetic laser surgery. Mosby, 2000:209-222.

45. Barton JK, Frangineas G, Pummer H, Black JF. Cooperative phenomena in two-pulse, two-colour laser photocoagulation of cutaneous blood vessels. Photochem Photobiol 2001;73:642-650.

46. Adrian RM. Cutaneous cooling facilitated high fluence pulsed dye laser therapy of port wine stains. Laser Surg Med 1995; 7:57.

47. Alster T. Preoperative patient considerations. In: Cutaneous laser techniques. 2nd ed. Philadelphia: Lippincott Williams& Wilkins,1999:13-32.

48. Alster T. Skin care and maintenance after laser treatment. In: Cutaneous laser techniques. 2nd ed. Philadelphia: Lippincott Williams& Wilkins, 1999:167-171.

49. Raulin C, Kimmig W; Werner S. Laser therapy in dermatology and esthetic medicine. Side effects, complications and treatment errors. Hautarzt 2000;5(7):463-473.

50. *Alster T. Side effects and complications of laser surgery. In: Cutaneous laser techniques. 2nd ed. Philadelphia: Lippincott Williams& Wilkins,1999:175-176.*
51. *Alster T.Side effects and complications of laser surgery. In: Cutaneous laser techniques. 2nd ed. Philadelphia: Lippincott Williams& Wilkins, 1999:175-180.*
52. *Levy JL, Elbahr C, Jouve E, Mordon S. Comparison and sequential study of long pulsed Nd:YAG 1064 nm laser and sclerotherapy in leg telangiectasias treatment.*
*Lasers Surg Med 2004;34(3):273-276.*
53. *Tiel H, Drosner M, Hebel T, Raulin C. New cooling technique for pulsed lasers or intensive light sources. Lasers Surg Med, Suppl 1998;10:16.*
54. *Drosner M. Blue facial teleangiectasia: Selective photo coagulation by alexandrite laser (case report). Med Laser Appl 2001; 16:156.*
55. *Hellbrugge G, Stockmeier M, Henschel R, Drosner M. Port wine stains: comparison of intense pulsed light and pulsed dye laser. Lasers Surg med, Suppl 2004;16:14.*

**Correspondence address:**
Mag. sc. Metka Adamič, dr.med.
Dermatološki center Parmova
Parmova 53, 1000 Ljubljana, Slovene
Tel.+386 1 43 66 330, e-mail: metka.adamic@dcp.si